Terms: = Prostate cancer AND RAC1, ENSG00000136238, 5879, MIG5, MGC111543, P63000, p21-Rac1, TC-25
126 results:
1. RhoU forms homo-oligomers to regulate cellular responses.
Clayton NS; Hodge RG; Infante E; Alibhai D; Zhou F; Ridley AJ
J Cell Sci; 2024 Jan; 137(2):. PubMed ID: 38180080
[TBL] [Abstract] [Full Text] [Related]
2. Synthetic and natural guanidine derivatives as antitumor and antimicrobial agents: A review.
Gomes AR; Varela CL; Pires AS; Tavares-da-Silva EJ; Roleira FMF
Bioorg Chem; 2023 Sep; 138():106600. PubMed ID: 37209561
[TBL] [Abstract] [Full Text] [Related]
3. Ketorolac modulates Rac-1/HIF-1α/DDX3/β-catenin signalling via a tumor suppressor prostate apoptosis response-4 (Par-4) in renal cell carcinoma.
Sonawane V; Ghosalkar J; Achrekar S; Joshi K
Sci Rep; 2023 Apr; 13(1):5659. PubMed ID: 37024613
[TBL] [Abstract] [Full Text] [Related]
4. TRPM8 as an Anti-Tumoral Target in prostate cancer Growth and Metastasis Dissemination.
Grolez GP; Chinigò G; Barras A; Hammadi M; Noyer L; Kondratska K; Bulk E; Oullier T; Marionneau-Lambot S; Le Mée M; Rétif S; Lerondel S; Bongiovanni A; Genova T; Roger S; Boukherroub R; Schwab A; Fiorio Pla A; Gkika D
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743115
[TBL] [Abstract] [Full Text] [Related]
5. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract] [Full Text] [Related]
6. A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer.
Hofbauer SL; Luger F; Harland N; Plage H; Reimann M; Hollenbach M; Gusenleitner A; Stenzl A; Schlomm T; Wiemer L; Cash H
BJU Int; 2022 May; 129(5):648-654. PubMed ID: 34773679
[TBL] [Abstract] [Full Text] [Related]
7. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance rac1-ERK-STAT3 signaling in hepatocellular carcinoma.
Wang LL; Luo J; He ZH; Liu YQ; Li HG; Xie D; Cai MY
Cell Death Dis; 2021 Nov; 12(11):1052. PubMed ID: 34741044
[TBL] [Abstract] [Full Text] [Related]
8. Cell-to-cell contact-mediated regulation of tumor behavior in the tumor microenvironment.
Sato A; Rahman NIA; Shimizu A; Ogita H
Cancer Sci; 2021 Oct; 112(10):4005-4012. PubMed ID: 34420253
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer.
Meng F; Han X; Min Z; He X; Zhu S
Aging (Albany NY); 2021 Jul; 13(13):17442-17461. PubMed ID: 34229299
[TBL] [Abstract] [Full Text] [Related]
10. Hormone-Dependent prostate cancers are Dependent on Rac Signaling for Growth and Survival.
Goka ET; Mesa Lopez DT; Lippman ME
Mol Cancer Ther; 2021 Jun; 20(6):1052-1061. PubMed ID: 33722851
[TBL] [Abstract] [Full Text] [Related]
11. HACE1 blocks HIF1α accumulation under hypoxia in a rac1 dependent manner.
Turgu B; Zhang F; El-Naggar A; Negri GL; Kogler M; Tortola L; Johnson F; Ng T; Li A; Yapp D; Lockwood W; Martinez D; Maris JM; Daugaard M; Penninger JM; Hughes CS; Sorensen PH
Oncogene; 2021 Mar; 40(11):1988-2001. PubMed ID: 33603169
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of microRNA-300 inhibits cell adhesion, migration, and invasion of prostate cancer cells by promoting the expression of
Li L; Hao J; Yan CQ; Wang HF; Meng B; Cai SY
Cell Cycle; 2020 Nov; 19(21):2793-2810. PubMed ID: 33064976
[TBL] [Abstract] [Full Text] [Related]
13. Effects of Arf6 downregulation on biological characteristics of human prostate cancer cells.
Lei H; Ma F; Jia R; Tan B
Int Braz J Urol; 2020; 46(6):950-961. PubMed ID: 32822124
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of active rac1 levels in cancer cells: A case of misleading conclusions from immunofluorescence analysis.
Baker MJ; Cooke M; Kreider-Letterman G; Garcia-Mata R; Janmey PA; Kazanietz MG
J Biol Chem; 2020 Oct; 295(40):13698-13710. PubMed ID: 32817335
[TBL] [Abstract] [Full Text] [Related]
15. Identifying and treating ROBO1
Ferrari MG; Ganaie AA; Shabenah A; Mansini AP; Wang L; Murugan P; Davicioni E; Wang J; Deng Y; Hoeppner LH; Warlick CA; Konety BR; Saleem M
Prostate; 2020 Sep; 80(13):1045-1057. PubMed ID: 32687658
[TBL] [Abstract] [Full Text] [Related]
16. HACE1 Prevents Lung Carcinogenesis via Inhibition of RAC-Family GTPases.
Kogler M; Tortola L; Negri GL; Leopoldi A; El-Naggar AM; Mereiter S; Gomez-Diaz C; Nitsch R; Tortora D; Kavirayani AM; Gapp BV; Rao S; Uribesalgo I; Hoffmann D; Cikes D; Novatchkova M; Williams DA; Trent JM; Ikeda F; Daugaard M; Hagelkruys A; Sorensen PH; Penninger JM
Cancer Res; 2020 Jul; 80(14):3009-3022. PubMed ID: 32366477
[TBL] [Abstract] [Full Text] [Related]
17. POTEE promotes colorectal carcinoma progression via activating the rac1/Cdc42 pathway.
Xu Q; Chen J; Peng M; Duan S; Hu Y; Guo D; Geng J; Zhou J
Exp Cell Res; 2020 May; 390(1):111933. PubMed ID: 32142855
[TBL] [Abstract] [Full Text] [Related]
18. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract] [Full Text] [Related]
19. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of Cdc42-intersectin interaction by small molecule ZCL367 impedes cancer cell cycle progression, proliferation, migration, and tumor growth.
Aguilar BJ; Zhao Y; Zhou H; Huo S; Chen YH; Lu Q
Cancer Biol Ther; 2019; 20(6):740-749. PubMed ID: 30849276
[TBL] [Abstract] [Full Text] [Related]
[Next]
